Tri Locum Partners LP Immatics N.V. Transaction History

Tri Locum Partners LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$7.36 - $10.89 $217,061 - $321,167	-29,492 Reduced 9.67%	275,482 $2.9 Million
Q3 2023 Nov 14, 2023	BUY	$11.01 - $12.62 $2.45 Million - $2.81 Million	222,922 Added 271.68%	304,974 $3.53 Million
Q2 2023 Aug 14, 2023	BUY	$5.92 - $12.72 $485,747 - $1.04 Million	82,052 New	82,052 $946,000
Q2 2021 Aug 16, 2021	SELL	$10.43 - $12.81 $1.27 Million - $1.56 Million	-121,743 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$10.24 - $14.6 $1.25 Million - $1.78 Million	121,743 New	121,743 $1.37 Million

101

75.8M

238K

727K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $522M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Tri Locum Partners LP, based on Form 13F filings with the SEC.

Stay updated on Tri Locum Partners LP with notifications on news.